Gedeon Richter UK
Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals
February 17, 2026Manufacturing and Production Gedeon Richter UK, Neurology
Gedeon Richter UK has announced its acquisition of full marketing and distribution rights to Reagila (cariprazine), a schizophrenia treatment, from …
Latest content
Highlighting the value of lab research for healthcare innovation
November 2, 2026
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
